ストックスクリーナーアプリを入手
2.13
0.00%
0.00
アフターアワーズ：
2.19
0.06
+2.82%
前日終値:
$2.13
開ける：
$2.12
24時間の取引高:
11,914
Relative Volume:
0.17
時価総額：
$104.47M
収益：
-
当期純損益:
$-9.51M
株価収益率:
-11.21
EPS:
-0.19
ネットキャッシュフロー:
$-10.96M
1週間 パフォーマンス:
+2.90%
1か月 パフォーマンス:
-7.39%
6か月 パフォーマンス:
+52.14%
1年 パフォーマンス:
+32.30%
1日の値動き範囲:
$2.12
$2.183
1週間の範囲:
$2.09
$2.1858
52週間の値動き範囲:
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
MNOV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
2.13 | 104.47M | 0 | -9.51M | -10.96M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-10 | 開始されました | Maxim Group | Buy |
| 2019-03-25 | 再開されました | B. Riley FBR | Buy |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 開始されました | Credit Suisse | Outperform |
| 2013-01-04 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2012-05-24 | ダウングレード | MLV & Co | Buy → Hold |
| 2011-10-18 | 繰り返されました | MLV Capital | Buy |
| 2011-06-22 | 開始されました | Global Hunter Securities | Buy |
| 2010-05-12 | 開始されました | Wedbush | Outperform |
| 2008-11-12 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2008-05-15 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 開始されました | Punk, Ziegel & Co | Buy |
すべてを表示
Medicinova Inc (MNOV) 最新ニュース
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Time to Sell? - Defense World
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - MarketBeat
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - Defense World
MediciNova (NASDAQ:MNOV) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial… - MSN
MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial - Smartkarma
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
Drug Trial Shows Positive Interim Results for ALS Treatment - Streetwise Reports
MediciNova Presents Study Update and Interim Analysis of - GlobeNewswire
MediciNova Reports Strong Interim Data from ALS Drug Trial, Shows Promising Correlations - StockTitan
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at D. Boral Capital - Defense World
MediciNova stock undervalued? D. Boral sees upside in ALS & MS market opportunities - Investing.com India
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Zacks sees 400% upside for MediciNova amid incoming damages from Sanofi/Novartis dispute - Kursiv Media
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement - Smartkarma
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement… - MSN
MediciNova, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
MediciNova reports progress in ALS and Long COVID trials - Investing.com
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders - GlobeNewswire
MediciNova Partners with NIH for ALS Trial, Reports $42.3M Cash Position | MNOV Stock News - StockTitan
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - The Manila Times
MediciNova Receives Notice of Allowance from United States - GlobeNewswire
MediciNova Secures Key Patent for Diabetes Treatment MN-001 Through 2042 | MNOV Stock News - StockTitan
MediciNova stock hits 52-week high at $2.17 amid growth - Investing.com India
MediciNova: Q3 Earnings Snapshot - Darien Times
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
MediciNova stock hits 52-week high at $2.17 amid growth By Investing.com - Investing.com UK
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis - The Manila Times
MediciNova Secures Major Settlement from Sanofi-Novartis Litigation, Boosts Clinical Pipeline | MNOV Stock News - StockTitan
Idiopathic Pulmonary Fibrosis Management Market Share and Size Report 2024-2031 - InsightAce Analytic
MediciNova (NASDAQ:MNOV shareholders incur further losses as stock declines 11% this week, taking five-year losses to 80% - Simply Wall St
MediciNova (NASDAQ:MNOV) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Medicinova Inc (MNOV) 財務データ
収益
当期純利益
現金流量
EPS
0.60%
2.24%
大文字化:
|
ボリューム (24 時間):